Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00740246 · ClinicalTrials.gov registry record · Phase 3
Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia
A Phase 3 study of Anemia, sponsored by American Regent.
- Completed
- Registry status
- Phase 3
- Development phase
- 594
- Enrollment target
- 1
- Study location
NCT00740246: Completed Phase 3 study of Anemia, sponsored by American Regent.
NCT00740246 is a Phase 3 study of Anemia that has completed, run by American Regent. The registered enrollment target is 594 participants, above the 419-participant average among 72 other Anemia trials with a reported enrollment target (42% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00740246, a Phase 3 study of Anemia, has completed, sponsored by American Regent.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 594 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate the safety and tolerability of VIT-45 in the treatment of Iron Deficiency Anemia
Primary Outcome
Number of participants with any treatment-emergent adverse events experienced by participants. The 7-day study period for Study Period 1 ended with the initiation of dosing for Study Period 2. The 7-day study period fo Study Period 2 ended with the completion of Day 14 procedures.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VIT-45
Study Locations (1)
Pennsylvania
- Luitpold Pharmaceuticals - Norristown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 594 participants |
| Start Date | 2005-07 |
| Est. Completion | 2006-05 |
| Phase | Phase 3 |
What the finished NCT00740246 record still lists
NCT00740246 is an interventional study that assigns participants to a tested intervention. The registered 594 participants enrollment target is mid-sized for trials with a published cap, above the 419-participant average among 72 other Anemia trials with a reported enrollment target (42% higher).
The record links to 1 condition, with Anemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00740246 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00740246 about?
NCT00740246 is a clinical study titled "Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia". The objective of this study is to evaluate the safety and tolerability of VIT-45 in the treatment of Iron Deficiency Anemia
What is the current status of trial NCT00740246?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 594 participants. The study started on 2005-07. Estimated completion is 2006-05.
What conditions does trial NCT00740246 study?
This clinical trial studies the following conditions: Anemia.
What interventions are being tested in trial NCT00740246?
The interventions under investigation include: Placebo (DRUG), VIT-45 (DRUG).
Who is sponsoring clinical trial NCT00740246?
This trial is sponsored by American Regent, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00740246 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00740246's enrollment target sits among peer trials
594 13th of 72 higher than 60 of 72 other Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
RECRUITING · Phase 3
-
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
ACTIVE NOT RECRUITING · Phase 3
-
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ACTIVE NOT RECRUITING · Phase 3
-
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
ACTIVE NOT RECRUITING · Phase 3
-
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04701684 · 594 participants · NA
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
- NCT05491213 · 594 participants · NA
TELESCOPE- TELEhealth Shared Decision-making COaching
- NCT05867420 · 594 participants · Phase 1
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
- NCT06890884 · 594 participants · Phase 2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia